Your browser doesn't support javascript.
loading
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
van den Bent, Martin J; Klein, Martin; Smits, Marion; Reijneveld, Jaap C; French, Pim J; Clement, Paul; de Vos, Filip Y F; Wick, Antje; Mulholland, Paul J; Taphoorn, Martin J B; Lewis, Joanne; Weller, Michael; Chinot, Olivier L; Kros, Johan M; de Heer, Iris; Verschuere, Tina; Coens, Corneel; Golfinopoulos, Vassilis; Gorlia, Thierry; Idbaih, Ahmed.
Afiliação
  • van den Bent MJ; Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: m.vandenbent@erasmusmc.nl.
  • Klein M; Brain Tumor Center and Department of Medical Psychology, VU University Medical Center, Amsterdam, Netherlands.
  • Smits M; Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands.
  • Reijneveld JC; Brain Tumor Center and Department of Medical Psychology, VU University Medical Center, Amsterdam, Netherlands.
  • French PJ; Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Clement P; Department of Oncology, KU Leuven and Department of General Medical Oncology, UZ Leuven, Leuven Cancer Institute, Leuven, Netherlands.
  • de Vos FYF; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
  • Wick A; Neurology Clinic, University of Heidelberg, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
  • Mulholland PJ; Department of Medical Oncology, University College London Hospital, London, UK.
  • Taphoorn MJB; Department of Neurology, MC Haaglanden, The Hague, Netherlands.
  • Lewis J; Freeman Hospital, Newcastle, UK.
  • Weller M; Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Chinot OL; Neuro-Oncology Division, Aix-Marseille University, AP-HM, Marseille, France.
  • Kros JM; Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • de Heer I; Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Verschuere T; European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
  • Coens C; European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
  • Golfinopoulos V; European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
  • Gorlia T; European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
  • Idbaih A; The Brain and Spine Institute (ICM), Sorbonne Université, The National Institute of Health and Medical Research (INSERM), National Centre for Scientific Research (CNRS), Public Assistance-Paris Hospitals (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France.
Lancet Oncol ; 19(9): 1170-1179, 2018 09.
Article em En | MEDLINE | ID: mdl-30115593
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Antineoplásicos Alquilantes / Bevacizumab / Antineoplásicos Imunológicos / Temozolomida / Glioma / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Antineoplásicos Alquilantes / Bevacizumab / Antineoplásicos Imunológicos / Temozolomida / Glioma / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article